Loading...
XBRU
OXUR
Market cap670kUSD
, Last price  
EUR
Name

Oxurion NV

Chart & Performance

D1W1MN
XBRU:OXUR chart
P/E
—
P/S
—
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
-49.41%
Rev. gr., 5y
-76.22%
Revenues
3k
-98.86%
3,243,0001,252,00030,421,0004,213,0006,175,0002,476,00075,083,000112,781,00013,776,00011,198,0007,104,0005,810,0005,320,0003,946,0002,077,9991,128,000595,000263,0003,000
Net income
119k
P
-10,134,000-15,967,00012,095,000-14,070,000-13,942,000-21,637,00030,415,00026,401,000-51,115,000-37,884,000-60,314,00022,788,000-38,474,000-51,827,000-28,012,000-29,158,000-31,685,000-18,969,000119,000
CFO
-2m
L-78.82%
-8,418,000-14,797,00011,957,000-12,098,000-16,842,000-19,564,00027,789,00025,710,000-46,579,000-27,793,000-20,309,00026,295,000-31,116,000-31,100,000-27,097,000-27,155,000-20,016,000-9,765,000-2,068,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
URL
https://www.oxurion.com
IPO date
Jul 07, 2006
Employees
27
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT